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The advancement of therapy for cardiovascular disease (CVD) is paramount to 
public health, as it is the leading global cause of mortality [1]. Nanomedicine provides 
new opportunities in the ongoing efforts to reduce the economic and healthcare 
consequences of CVD. Carbon Nanodots (CNDs) green-synthesized from microwave 
pyrolysis of ethylenediamine and citric acid are spherical, ~3 nm in diameter, and possess 
exceptional hydrophilic, biocompatible, fluorescent, and anti-oxidant properties. 
However, there is no current report on how these CNDs affect the cardiovascular system, 
particularly their potential in mediating endothelial dysfunction and cardiovascular 
disease (CVD). As a known biomarker of inflammation, Oxidized-LDL (Ox-LDL) 
induces inflammatory gene expression and monocyte extravasation that leads to 
atherosclerotic development. This study examines the role of CNDs in mediating Ox-
LDL induced inflammation in human microvascular endothelial cells (HMEC-1). Our 
results demonstrate that CNDs can reduce Ox-LDL induced monocyte adhesion in 
HMEC-1s, which demonstrates their anti-inflammatory effects. The relative gene 
expression of the cytokine interleukin-8 (IL-8) was reduced by the addition of CNDs, 
which implies their action in mediating monocyte recruitment to the site of inflammation. 
While reactive oxygen species (ROS) perform many essential functions, their 
overproduction disrupts cellular oxidative balance, induces EC dysfunction, and leads to 
an inflammatory state. Studying the action of CNDs through Electron paramagnetic 
resonance (EPR) spectroscopy showed direct superoxide and hydroxyl radical-
scavenging by CNDs. This result implies that the anti-inflammatory effects of CNDs seen 
in vitro are attributed to their direct scavenging of ROS. Furthermore, CNDs were found 
to ameliorate the cytotoxicity caused by Ox-LDL in HMEC-1s. Viability assays showed 
CNDs were not cytotoxic at measured concentrations to HMEC-1s in vitro. Animal 
studies involving mice did not show any morphological or physical changes between the 
CND and control groups. These collective results demonstrate the potential of CNDs to 
reduce inflammation and cytotoxicity caused by Ox-LDL in HMEC-1s, which implies 
their use in the development of novel therapy for cardiovascular disease. 
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CHAPTER I 
 
INTRODUCTION 
 
 
The prevalence of cardiovascular disease (CVD) and its impact on global health 
have been a cause of intense concern and research. The accumulation of plaque within 
arterial walls causes the diameter of the arterial lumen to decrease and restrict blood flow 
rate and volume. This condition is termed atherosclerosis and can lead to major cardiac 
and neural pathologies. Clinical manifestations of CVD can be in the form of myocardial 
infarction (MI), peripheral arterial disease, ischemic heart disease and stroke [2]. CVD 
presents an overwhelming economic and public welfare challenge, as it causes 30% of all 
deaths worldwide. Medicaid database results show CVD treatment is more expensive 
than diabetes, anxiety, and hypertension. In fact, one American dies every 36 seconds 
from some form of CVD [3].  
As the demographics of Americans in terms of obesity rates and average age are 
increasing, the preventive and therapeutic treatment of CVD is at its most crucial point. 
One of the challenges of developing novel or improved methods for treatment or 
prevention of CVD is to identify the exact mechanism of development. One of the 
causative factors of CVD is reactive oxygen species (ROS), which can hasten 
dysfunction and cause downstream effects [4]. Thus, it is essential to identify the point at 
which controlling pathogenic ROS can halt or even reverse the progression of 
atherosclerosis.
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Oxidative Stress and Atherosclerosis 
Given the numerous complex mechanisms behind atherosclerosis, excess 
production of ROS has been shown to be one of the key contributing factors to its 
progression. ROS can be radicals, as in the case of the hydroxyl radical (·OH) or 
superoxide (·O2-). Others can be oxidizers, such as hydrogen peroxide (H2O2) and 
peroxynitrite (ONOO-) [5, 6].  At low concentrations, ROS play a key role in helping 
endocrine balance, neuronal firing, enzyme activity and ion exchange. In fact, genetic 
defects that lead to limited ROS production are deleterious when dealing with pathogens 
as part of the innate immune response. Mitochondrial ROS are also involved in toll-like 
receptor (TLR) action which is used by sentinel immune cells [7]. H2O2 at low 
concentrations is used as a signaling molecule due to its longer half-life and ability to 
diffuse across membranes. Thus, ROS are essential components of cells and help to 
signal pathways throughout the body. However, overproduction of ROS disrupts 
homeostasis, causing endothelial inflammation and development of plaque.  
The extreme chemical reactivity of ROS can cause damage to cellular 
macromolecules, membranes, and organelles. This occurs in abundance in blood vessels, 
which have high mitochondrial activity due to the continuous action of the heart [5]. 
Oxidative stress can occur at this point, which has many implications for cell viability 
and function. ROS overproduction is not just causative of CVD but also insulin 
resistance, obesity and metabolic syndrome [7]. The production of ROS is in large part 
due to the mitochondrial electron transport chain (ETC), xanthine oxidase, 
myeloperoxidase (MPO), nitric oxide synthase (NOS), lipoxygenase and nicotinamide 
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adenine dinucleotide phosphate oxidase (Nox). Nox reduce oxygen to form O2
•- that are 
utilized by monocytes and neutrophils against pathogens [2]. Within the ETC, 2-3% of 
electrons are leaked and cause the formation of O2
•-. Many other cardiac cells such as 
vascular endothelial cells and cardiomyocytes express Nox variants that produce 
pathogenic and regulatory ROS. Thus, cardiovascular cells are highly susceptible to 
oxidative stress due to their level of activity and capability of overproducing ROS.  
Firstly, some of the proteins producing superoxide radicals (O2
•-) are Nox types 
1,2 and 5, which are known inducers of apoptosis in ECs [5]. Hypertension and 
angiotensin II receptor activity can lead to these forms of Nox overexpressing 
themselves, which further damages the vasculature. ApoE -/- mice without Nox2 showed 
a decrease in lesions, aortic ROS production, further confirming that inhibition of this 
isoform can be beneficial [8, 9]. In humans, Nox5 abundance and expression are 
heightened in coronary arteries with plaque buildup [7]. Secondly, endothelial NOS 
enzymes (eNOS) are abundant in the cardiovascular system, and they are heavily 
involved in ROS production. They facilitate electron transfer and convert L-arginine to 
L-citrulline. Uncoupling of eNOS from the electrons flowing through can cause reduction 
of molecular oxygen. Clinical studied in patients with diabetes and atherosclerosis 
showed increased eNOS uncoupling, leading to the production of O2
•- [2]. In addition to 
this, genetic and environmental factors can also lead to increased ROS generation. For 
instance, studies on apolipoprotein E knockout (ApoE -/-) mice showed increased eNOS 
expression, atherosclerotic lesions, and O2
•- generation [10].   
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Oxidized LDL: A Biomarker of Inflammation 
ROS can oxidize low-density lipoproteins (LDL) and induce the formation of 
foam cells, which is the preliminary step to the development of plaque [11, 12]. The 
increase in ROS leads to EC dysfunction and vascular smooth muscle cell (SMC) 
proliferation and migration, both of which augment atherogenesis. LDL distribution in 
organs and time spent in circulation is governed by its size, which also influences cell-
mediated endocytosis [13]. The oxidation of LDL (ox-LDL) is a well-established 
preliminary step of atherosclerosis, indicating its position as a risk factor for CVD. In 
healthy patients, CVD can be predicted by measuring ox-LDL levels, which further 
underscores their role as biomarkers of atherosclerosis. The protein moiety in LDL has 
been stained using immunohistochemistry, and results showed high concentration in 
atherosclerotic plaques [14]. LDL detaches from its transport vehicle in circulation and 
enters the arterial wall, where it comes in contact with oxidants from ECs. Transition 
metal ions or other catalysts can oxidize LDL, which leads to the inflammatory cascade 
and a positive feedback loop to make more ox-LDL [2, 15].  
The progress of pre-atherosclerotic activity and its relation to ox-LDL is 
explained by macrophage uptake. These scavengers form foam cells that have abundant 
cholesteryl ester and cause EC dysfunction due to receptor-mediated ox-LDL uptake. The 
immune response against ox-LDL produces autoantibodies, which are elevated in the 
presence of atherosclerosis. It also increases the expression inflammatory cytokines, 
chemokines, and adhesion molecules in EC and monocytes. When ROS pose a threat to 
endothelial and underlying cells, these WBCs are guided to the site of inflammation. The 
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expression of inflammatory chemokines and cytokines like interleukin-8 (IL-8) and 
monocyte chemoattractant protein 1 (MCP-1/CCL2) further promotes leukocyte 
extravasation [16-19]. WBCs are also attracted by intracellular adhesion molecules 
(ICAM), VCAM, P-selectin and E-selectin [20]. The expression of these known 
inflammatory markers such as MCP-1 and VCAM-1 is induced in endothelial cells by the 
overproduction of ROS.  
The lipids in highly ox-LDL become pro-apoptotic and cytotoxic as they develop 
in the intima-media [15]. Maturing atherosclerotic lesions have a lipid interior and a 
fibrous cap, which is weakened by necrosis and other events within the blood vessels. 
Apoptotic macrophages undergo autophagy but failed to carry out this process releases 
Nox and ROS, which expedites plaque rupture [7]. The rupture causes thrombosis, 
abruptly stopping blood and leading to MI or other forms of cardiac damage. The 
extracellular matrix around these cells can also be modified during ROS exposure, with 
increased leukocyte extravasation and remodeling via matrix metalloproteinases (MMPs) 
[5]. 
The Need for Improvement in Anti-Inflammatory Pharmacotherapy 
Decades of laboratory and clinical trials have created therapies to treat and 
prevent ROS-mediated CVD. Antioxidants have been used to prevent ROS buildup and 
impede the inflammatory cascade. Lane et al. demonstrated the use of Vitamins A, C, and 
E lowers arterial dysfunction leading to disease. [5] It is important to note that 
antioxidant therapy has been largely unsuccessful in clinical trials. While ROS are 
important in CVD pathology, there are beneficial ROS that antioxidant therapy targets 
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without treating the underlying mechanism [20]. Thus, antioxidant therapy fails to be the 
pharmaceutical solution to treatment and prevention of CVD.  
Some of the major classes of drugs used to ameliorate multiple effects of CVD are 
statins and angiotensin-converting-enzyme (ACE) inhibitors. Statins induce endothelial 
nitric oxide synthase (eNOS) action to indirectly combat EC damage and plaque 
formation [21]. Angiotensin II type I receptor blockers (ARBs) an also play a synergistic 
role in combating oxidative stress by decreasing carotid artery wall thickness and the 
amount of oxidative stress. Aspirin is also used in preventative ways to reduce MI risk, 
but its effect on stroke and CVD has not been conclusive [22]. However, they are debated 
in terms of use and side effects in high-risk populations.  
The aforementioned drugs are not without their short- and long-term side effects, 
which calls for a moderated and individualistic approach by healthcare professionals [23]. 
The limitations of these therapies are short half-life in vivo, restricted bioavailability, and 
inability to permeate some biological membranes. Due to ROS-induced inflammation and 
its role in the progression of atherosclerosis, steroidal and non-steroidal anti-
inflammatory drugs have been used to combat the inflammatory cascade. Thus, the side 
effects of these drugs create a need for better anti-inflammatory pharmacotherapy. This 
demand is leading the way for innovation in the form of nanomedicine, which can extend 
the boundaries of traditional pharmacotherapies and be a significant positive impact on 
the lives of atherosclerotic patients.  
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Nanomaterials in Oncologic and Cardiovascular Treatment 
Nanomedicine provides new opportunities in the ongoing battle against reducing 
the health and economic damage caused by CVD. Nanotechnology allows the application 
of engineering to biological systems, which can create multi-disciplinary solutions to 
pathologies. The inherent properties of nanoparticles can be used for imaging and therapy 
for a variety of disorders that characterize CVD. Their chemical stability allows their 
interaction with membranes and fluids within the body, and their small size makes 
translocation possible [24-28].  
Nanoparticles are distinct from macroscopic structures due to their sizes below 
100 nm and unique physical, optical, mechanical and chemical properties. The properties 
of nanomaterials, such as structure, surface composition, and chemical reactivity dictate 
their effects in biological systems [13]. Surface passivation with homing ligands like 
monoclonal antibodies, peptides, or their mimetics can make targeting of specific 
biomarkers possible [29]. Poly(lactide-co-glycolide) (PLGA) nanoparticles in vivo 
caused a significant decrease in inflammatory monocyte subsets as compared to non-
inflammatory monocytes, which shows their regulatory effects on the immune system 
[13]. Additionally, lipid-latex (LiLa) hybrid nanoparticles with phagocytic signals have 
been used to image and be vehicles in atherosclerotic models. These LiLa NPs were able 
to carry hydrophobic drugs and target inflammatory WBCs, while demonstrating steady 
drug release kinetics [30].  
The multifaceted nature of NPs gives rise to a new ‘theranostic’ approach that 
combines the diagnostic capability of functionalized NPs with subsequent therapeutic 
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drug release. The events corresponding with plaque ruptures such as MMP upregulation, 
fibrous cap weakening, fibrin deposition, and macrophage concentration are all detectable 
by nano-theranostic means [31]. Nanoparticles have been successfully used for molecular 
imaging of plaque angiogenesis and lipoproteins [32]. The detection of CVD is equally 
challenging and essential due to the rapid reactivity of ROS with macromolecules. 
Traditional techniques are not able to fully detect the inflammatory process that leads to 
atherosclerotic lesions, and most fatal MIs are not detectable using x-ray angiography 
[33]. Nano-bioimaging can reveal where these reactions are taking place and detect their 
downstream effects. Although the proposed mechanism of LDL oxidation has been 
outlined, its exact location, progression, and cofactors have not been fully determined. 
For example, oxidized phospholipids (OxPL) in ox-LDL can be tracked and predict 
chances of MI, stroke, and other CVD-related deaths. Cell adhesion molecules are vital 
players in the inflammatory cascade, and nano-imaging techniques can reveal 
mechanisms of their action in real time.  Thus, non-invasive imaging by NPs can enable 
early detection and preventative treatment of CVD [33].  
Carbon Nanodots (CNDs): Applications in Nanomedicine 
The medical applications of CNDs are highly dependent on their mechanism of 
interaction in the body. Semiconductor quantum dots (SQDs) were explored in this aspect 
due to their easy synthesis, optical properties, and photostability. However, their 
preparation required toxic metal ions and demonstrated oxidative degradation that 
challenged the safety of their use in biological systems [34]. SQDs can cause leaching of 
heavy metals and oxidation, which pose significant limitations in their medical use. There 
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have been attempts to reduce SQD toxicity by coating with polymers and hydrophilic 
chemicals, but there remains a need for economically produced and biocompatible 
nanoparticles. 
Carbon nanodots (CNDs) are a novel addition to the family of nanomaterials, with 
exceptional biocompatibility, stability, fluorescence, and photoluminescence. The typical 
CND is < 10 nm and has a lattice spacing that resembles that of graphite with a chemical 
composition of carbon, oxygen, and surface functional groups. These functional groups 
help polarize the CND, making it hydrophilic and thus readily dispersible across most 
biological membranes. CNDs have an inner sp2 and outer sp3 hybridized structure that 
often has oxygen-containing functional groups. CNDs generally have a spherical shape, 
but varying synthetic methods can give crystalline structures [35]. 
The various methods of preparing CNDs can be classified broadly into a top down 
or bottom up syntheses. Top-down methods generally involve a larger carbon source 
being fragmented into increasingly smaller particles using hydrothermal or solvothermal 
cutting, laser ablation, chemical oxidation releasing or etching, and intercalation. Bottom-
up approaches involve carbonization of organic precursors to synthesize CNDs. These 
can involve ultrasonication, solvent-mediated microwave pyrolysis and refluxing 
pyrolysis, as well as dehydration with sulfuric acid. Microwave pyrolysis reduces the 
reaction time, decreases side reactions, and increases the yield of CNDs [36]. The 
resulting product can undergo centrifugation, dialysis, chromatography, electrophoresis 
and other methods to give uniformity [37]. The morphology and structure of CNDs are 
heavily dependent on the precursor, method of preparation and experimental conditions. 
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The development of green synthetic methods of preparing CNDs was essential to 
improving their economic and environmental impact. Fluorescent CNDs have been 
prepared from various sources such as glucose, coffee grounds, ethylenediamine-
tetraacetic acid (EDTA) salts, grass, soy milk and pomelo peels [38]. Hsu et al. were able 
to use a green-synthetic method to produce CNDs from coffee grounds. The grinding, 
heating, and separation process yielded the CNDs of diameter ~5 nm. FTIR analysis 
revealed surface caffeine, hydroxyl and carboxylate groups. The organic compounds in 
the coffee grounds provided hydrophilicity and passivation resulted in strong 
fluorescence [34]. The use of sweet potatoes to produce negatively charged CNDs was 
shown by Lu et al., which involved hydrothermal treatment of the complex carbohydrate. 
After reaching the point of supersaturation, burst nucleation resulted in fluorescent CNDs 
(1-3 nm) that could be used to detect Hg2+ [38]. Thus, green-synthetic CNDs were not 
only economical and relatively easy to produce, but they also had inherent properties that 
could be used to detect biologically active molecules.  
The photoluminescent (PL) properties of gold, lead, silver and silicon nanodots 
have been used to detect DNA proteins and metal ions. Although some have shown high 
sensitivity, they have high economic and environmental costs, lower yield, and optical 
instability. The chemically inert nature, photostability and unique PL qualities give CNDs 
an advantage over Au nanodots, Ag nanoclusters, and SQDs [35]. The stability of CNDs 
can be observed by dissolving them in aqueous solutions and storing them at 4 °C. 
Green-synthesized CNDs stored in these conditions were stable for months without 
precipitating out of solution or detectable change in PL intensity [38]. Oil-based CNDs 
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underwent UV excitation for 6 months and storage for an additional 6 months and 
showed no observable PL intensity change [39]. The PL intensity of CNDs continuously 
exposed to laser irradiation did not decrease [35]. As demonstrated by Hsu et al., CNDs 
continuously excited for 6 h with a Xe lamp did not show a change in PL intensity [34]. 
The average absorbance of CNDs in the UV region is 330 – 420 nm is influenced by 
photon harvesting and has a tail in the visible region. However, π-π* bond and ketone 
group transition can cause CNDs to have a 250 – 300 nm band. Their emission 
wavelength is dependent on size and generally within 400 – 600 nm [34].  
Green synthetic CNDs from coffee grounds were tested in LLC-PK1 cells to 
determine their internalization. Cell imaging revealed localization in the cytoplasm and 
cell membrane, possibly through endocytosis [34]. This demonstrated the ability of 
CNDs to remain stable and emit strong PL in culture media. 16HBE cells were treated 
with oil-based CNDs, and fluorescence imaging showed cytoplasmic localization after 
excitation at 488 nm.  However, the nuclear region was devoid of any fluorescence, 
signaling that CNDs may not interact with or disrupt genetic material [39]. CA/CU-
CNDs were observed in the membrane and cytoplasm of HeLa cells using multiphoton 
excitation fluorescence (MPEF) microscopy after a 24 hr incubation [40]. Thus, CNDs 
have been applied to biological systems in vitro and show their ability to cross 
membranes and thus interact with intracellular macromolecules.  
There is currently no report on CND effects on the cardiovascular system, 
particularly its anti-oxidative potential in mediating ox-LDL induced EC dysfunction. 
ECs are central players in maintaining homeostatic balance and mediating pathogenic 
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processes in the cardiovascular system [7]. They determine the diameter, permeability 
and flow rate in blood vessels. In addition, they modulate growth and remodeling of 
vasculature and stem cells. As regulators of leukocyte extravasation during inflammation, 
ECs are key components of the development of atherosclerosis. The Human 
microvascular endothelial cell line 1 (HMEC-1) was isolated and immortalized in order 
to represent primary cultures for the investigation of CVD. HMEC-1s are well 
characterized and retain many of primary endothelial characteristics such as surface 
molecules. The expression of adhesion molecules (ICAM-1 and VCAM-1) on these cells 
are similar to those of human umbilical vein endothelial cells (HUVECs), a common 
model for endothelial cell research [41]. 
The morphological, phenotypical, and functional properties of primary HMECs 
are retained in HMEC-1, making it an accurate model for the mechanisms of endothelial 
dysfunction [42].  HMEC-1s also demonstrate receptor-mediated LDL particle uptake, 
which enables their use in the study of atherosclerosis. The primary goal of this study is 
to investigate the role of CNDs in the modulation of Ox-LDL-induced inflammation in 
HMEC-1 cells. Ox-LDL is a known biomarker of inflammation, and it affects the 
expression of genes involved with inflammatory response and leukocyte extravasation. I 
hypothesize that the antioxidant properties of CNDs can prevent ox-LDL-induced 
endothelial inflammation. Hence, this study examined the effects of CNDs on ox-LDL-
induced endothelial cell dysfunction and their ability to ameliorate ox-LDL-mediated 
injury in HMEC-1s. The effect of CNDs on the health of C57BL/6 mice for 1 and 2 
weeks was evaluated according to body weight and histology. The elucidation of CND 
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impact on ECs can provide additional information on the potential application of these 
nanoparticles for the treatment of inflammatory disorders leading to atherosclerosis.
14 
CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Cell Culture 
HMEC-1 (ATCC® CRL-3243™) cells were grown in MCDB131 base medium 
without L-Glutamine. This was supplemented with 10 ng/mL Epidermal Growth Factor 
(EGF), 1 μg/mL Hydrocortisone, 10 mM Glutamine and a final concentration of 10% 
Fetal Bovine Serum (FBS). THP-1 cells were grown in RPMI-1640 medium 
supplemented with 10% FBS and 1% Pen-Strep. All cells were grown in Cellstar® Filter 
cap 75 cm2 cell-culture treated filter screw cap flasks in humidified incubators at 37 °C 
and 5% CO2. Respective media was renewed every 2 days, and cells were split into a new 
passage at 85% confluence.  
CND Synthesis 
Wendi Zhang (JSNN) synthesized CNDs by a microwave-assisted method using 
citric acid (0.96 g, 99%, ACROS Organics), 1.0 mL ethylenediamine (99%, Alfa Aesar) 
and 1.0 mL deionized H2O. This solution was mixed in a glass vial and heated in a 
microwave synthesizer (CEM Corp 908005) at 300 W for 18 minutes. The resulting 
solution was then dialyzed against DI-H2O (1000 MWCO, Fisher Scientific) for 24 hours. 
Then, a freeze-dryer (FreeZone 6, Labconco) was used to dry the solution, which gave 
the final solid product. 
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CND Characterization 
UV-Vis spectroscopy was carried out using the Cary® Eclipse TM Fluorescence 
Spectrophotometer. CNDs were diluted to a concentration of 2 mg/mL in DI-H2O and 
measured for fluorescence in a quartz cuvette. CNDS were excited at a wavelength of 
350 nm. Then, they were excited at wavelengths 300 – 400 nm at 20 nm increments and 
measured for emission. Fourier transform infrared spectroscopy (FTIR) was used by 
Wendi Zhang to study the chemical structure and elemental content of CNDs.  
Oxidation of LDL 
Human Low-density lipoprotein (LDL) (99%) at 5mg/ml in 0.05M TRIS-HCl 
buffer, with 0.15M NaCl and 0.3mM EDTA, and pH 7.4 was purchased from Alfa Aesar. 
The LDL was dialyzed against phosphate buffer for 24 hours at 4 °C to remove buffer 
salts and macromolecules greater than 2,000 Daltons. After the addition of 10 mM 
CuSO4, it was then incubated at 37 °C for 12 hours and used immediately for treatment. 
Ox-LDL was diluted to 25 – 100 μg/mL in 5 mL HBSS and added to cells. 
CND and Ox-LDL Treatments 
CND treatments were time-dependent, dose-dependent, and with or without co-
treatment of Ox-LDL. Time-dependent treatments were set up as 24, 12, 6 and 3 hours. 
Dose-dependent treatments were 1.2, 0.6, 0.3, 0.2, 0.1, 0.03, 0.003, and 0.0003 mg/mL 
CND. When treating with CNDs, cells were grown in 100 mm × 10 mm Corning® cell 
culture-treated Petri dishes in the same incubator conditions. The treatment medium for 
HMEC-1 was sterile, filtered Hank’s Balanced Salt Solution (HBSS) with 16 g NaCl, 0.8 
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g KCl, 0.06 g KH2PO4, 2 g Glucose, 0.096 g Na2HPO4, 0.28 g CaCl2, 0.7 g NaHCO3 and 
0.1 g MgCl2 per 2 liters of nanopure H2O at pH 7.4.  
CND Uptake Assay 
HMEC-1 cells were cultured in complete MCDB131 medium and treated with 0 – 
0.3 mg/mL CNDs at 85% confluence. After incubation at 37 °C, 5% CO2 for 6 hours, 
treatment medium was discarded. Cells were rinsed with PBS (pH 7.8) to remove any 
membrane-bound CNDs. Cells were collected and resuspended in 1 mL PBS (pH 7.4) 
and measured for fluorescence using the Bio-Tek® Synergy 2™ plate reader at 360/40 
excitation and 460/40 emission.  
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) 
Cells were cultured in respective medium in 100 mm × 10 mm Corning® cell 
culture-treated Petri dishes until 85% confluence and media were discarded. Fresh HBSS 
or medium containing CND and LDL concentrations as described previously was 
incubated for a predetermined amount of time. After the incubation period, cells were 
washed with 37 °C PBS and transferred to an RNase-free hood. TRIzol™ reagent was 
used to extract RNA from cells according to the ThermoFisher Scientific™ RNA 
isolation protocol. After dilution of RNA in 15 µL RNase-free diethylpyrocarbonate 
(DEPC)-treated water, the concentration was measured.  
RNA concentration and purity were determined by Thermo Scientific™ 
Nanodrop 2000, a full-spectrum UV-Vis spectrophotometer. Concentrations were 
normalized to 500 ng/µL, and cDNA was synthesized via reverse transcription. This used 
14.875 µL DEPC-treated water, 5 µL 5x First Strand Buffer, 1.25 µL deoxynucleotide 
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triphosphate (dNTP) solution, 1.25 µL Random Primers, 0.625 µL Moloney Murine 
Leukemia Virus Reverse Transcriptase (M-MLV RT) and 2 µL RNA per sample. The 
cDNA was synthesized in Applied Biosystems™ Veriti™ 96 Well Thermal Cycler. 
The genes of interest were targeted using 5 µL DEPC-treated water, 2 µL each of 
5 µM forward and reverse primers, 10 µL Power SYBR® Green PCR Master Mix and 
diluted cDNA (1:5). The target genes were IL-8, NQO1, and GCL-C with GAPDH 
serving as the housekeeping gene. The Applied Biosystems™ StepOnePlus™ Real-Time 
PCR System was run for 40 cycles at the following settings: 95 °C for 15 seconds, 58 °C 
for 1 minute, and 60 °C for 15 seconds. In order to quantify gene expression, the 
comparative threshold cycle (CT) values were used. 
IDT® Human Primer Sequences 
The primer sequences used are listed as follows: GAPDH Forward: 5’ – AGA 
ACG GGA AGC TTG TCA TC – 3’, GAPDH Reverse 5’ –  GGA GGC ATT GCT GAT 
GAT CT – 3’. IL-8 Forward: 5’ – CTC TGT GTG AAG GTG CAG TT – 3’, IL-8 
Reverse: 5’ – AAA CTT CTC CAC AAC CCT CTG – 3’. NQO-1 Forward: 5’ – TTA 
CTA TGG GAT GGG GTC CA – 3’ , NQO-1 Reverse: 5’ – TCT CCC ATT TTT CAG 
GCA AC – 3’. GCL,C Forward: 5’ – ACC ATC ATC AAT GGG AAG GA – 3’, GCL,C 
Reverse: 5’ – GCG ATA AAC TCC CTC ATC CA – 3’. 
Monocyte Adhesion Assay 
HMEC-1 cells were grown to confluence in Corning® tissue-culture treated 
culture dishes D × H 35 mm × 10 mm and treated with CNDs, Ox-LDL, or both for 6 
hours. Prior to the end of treatment, THP-1 cells were counted using a hematocytometer 
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to allow 7.3 × 105 cells per dish. Monocytes were centrifuged at 1,500 RPM for 6 
minutes and resuspended in 0.5% FBS RPMI in a 25 cm2 flask. Invitrogen™ Calcein, 
AM at a final concentration of 0.75 µM was added, and the flask was gently tapped to 
ensure dispersal. After incubation at 37 °C, 5% CO2 for 1 hour, THP-1 cells were 
centrifuged 1,500 RPM for 6 minutes and resuspended in 0.5% FBS RPMI media.  
Treatment from HMEC-1 cells was stopped, and calcein-labeled THP-1 
monocytes were added to facilitate binding. After 1 hour of incubation, cells were rinsed 
with PBS to remove unbound monocytes and collected. Cells were then resuspended in 1 
mL pH 7.4 PBS and spun 5,000 RPM for 5 minutes. The supernatant was decanted, and 
cells were resuspended in 1 mL PBS, after which they were transferred to a black, opaque 
96 well plate. The Bio-Tek® Synergy 2™ plate reader was used to measure fluorescence 
at excitation 485 nm, emission 520 nm.  
Antioxidant Enzyme Lysate 
Cells were treated with CNDs using the methods described previously. After the 
incubation period, cells were washed with PBS at 37 °C and incubated for 2 minutes to 
remove any remaining media. After decanting the PBS, 1.5 mL of trypsin was added per 
75 cm2 of cell growth surface area. The cells were incubated at 37 °C for 2 minutes, and 
trypsin was neutralized by the addition of 1 mL FBS and 10 mL growth medium. The cell 
suspension was centrifuged for 10 minutes at 1,500 RPM. The resulting pellet was 
suspended in 1 mL phosphate buffered saline (PBS). After centrifugation at 5,000 RPM 
for 5 minutes, the resulting pellet was resuspended in 300 µL sterile KH2PO4/K2HPO4 
tissue buffer with 2 mM EDTA. This solution was sonicated for 15-second intervals 4 
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times and centrifuged at 13,000 RPM for 5 minutes. The resulting supernatant was 
collected and immediately analyzed for proteins.  
Total Protein Concentration 
Total protein content was measured using 10 µL lysate and 790 µL Bio-Safe™ 
Coomassie Brilliant Blue G-250 stain. This mixture was vortexed and transferred to 
cuvettes for spectrophotometric analysis. Absorbance was measured at 595 nm using the 
Beckman-Coulter® DU800 spectrophotometer. This was compared to a 1.48 mg/mL 
Bovine Serum Albumin (BSA) standard to determine cellular protein concentration.  
Glutathione (GSH) Assay  
HMEC-1 cells were grown to confluence and exposed to CND concentrations 
previously discussed for 24 hours. The lysate was treated with meta-phosphoric acid and 
0.1% sodium phosphate buffer at pH 8.0 for 10 minutes. The resulting solution was 
centrifuged at 13,000 rpm for 5 minutes. The supernatant was incubated with 0.1% 
sodium phosphate buffer and o-phthalaldehyde (OPT) for 15 minutes. The fluorescence 
intensity was measured by excitation at 350 nm and emission at 420 nm. To account for 
interference with CNDs, samples were prepared in the same manner without OPT and 
measured. The difference between OPT and non-OPT was used as the final reading, 
which was calculated according to a 5 µg/mL GSH standard curve.  
Glutathione S-Transferase (GST) Assay 
The reaction mixture for measuring GST activity was prepared using 10 mL 0.1 
M phosphate buffer (pH 6.5), 30 mg BSA, 100 µL of 10 mM GSH, and 200 µL of 50 
mM 1-chloro-2,4-dinitrobenzene (CDNB) in ethanol. Then, 15 µL of lysate was mixed 
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with 585 µL reaction mixture in a cuvette and immediately transferred to a 
spectrophotometer, which read absorbance at 340 nm every 30 seconds for 5 minutes. A 
blank cuvette with 15 µL tissue buffer and 585 µL reaction mixture was run with each 
sample set.  
NAD(P)H Quinone Dehydrogenase 1 (NQO1) 
The reaction mixture for detecting NQO1 activity was prepared with 12 mL of 50 
mM Tris-HCL buffer (pH 7.5, 0.08% Triton X-100), 36 µL of 50 mM Nicotinamide 
adenine dinucleotide phosphate (NADPH) and 48 µL of Dichlorophenolindophenol 
(DCPIP). 4 µL of the lysate was added to 696 µL of this reaction mixture in a cuvette and 
analyzed by the Beckman-Coulter® DU800 spectrophotometer. The rate of DCPIP 
reduction reflected NQO1 activity, which was measured at an absorbance of 600 nm. 
Electron Paramagnetic Resonance (EPR) Spectroscopy 
Hydroxyl radicals (OH·) generated by the Fenton reaction were measured by spin 
trap 5,5 dimethylpyrroline-N-oxide (DMPO). The reaction was as follows: Fe2+ + H2O2 
→ Fe3+ + OH· + OH-. Thus, 10 mM DMPO, 50 µM FeSO4, 50 µM H2O2, with 0 – 0.3 
mg/mL CNDs were combined in PBS and transferred to a capillary tube at a final volume 
of 100 µL. Superoxide anions (·O2
-) were generated by the Xanthine/xanthine oxidase 
system and used spin trap 5-(Diethylphosphono)-5-methyl-1-pyrroline N-Oxide 
(DEPMPO). Thus, 0.1 mM DTPA, 10 mM DEPMPO, 360 µM xanthine and 32 mU/mL 
Xanthine Oxidase, with 0 – 0.3 mg/mL CNDs were combined in a capillary tube at a final 
volume of 100 µL. The EPR spectra were recorded at 25 °C using the Bruker D-200 ER, 
IBM-Bruker spectrometer operating at X-band with a TM cavity and capillary cell. The 
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settings for this spectrometer were as follows: modulation frequency, 100 kHz; X-band 
microwave frequency, 9.5 GHz; microwave power, 20 mW; modulation amplitude, 
1.0G(gauss); time constant, 160 s; scan time, 200 s; and receiver gain, 1×105. 
MTT Assay 
HMEC-1 cells were grown in clear 24-well Costar® cell-culture treated plates to 
85% confluence in respective media. Then, the culture medium was decanted and 
replaced with 300 µL/well of treatment medium. After the incubation at 37 °C and 5% 
CO2, the treatment was decanted, and 33 µL of 0.2 mg/mL (3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide) (MTT) was added. After 2 more hours of incubation, 
the MTT-containing solution was decanted, and 200 µL of dimethyl sulfoxide (DMSO) 
was added. Then, the plate was covered with aluminum foil and put on a shaker for 15 
minutes at low speed. After the formazan crystals had dissolved, absorbance was 
measured at 570 nm using the Bio-Tek® Synergy 2™ plate reader for quantification and 
analysis.  
Animal Project (Protocol 16-004) 
Male C57BL/6 mice were purchased from Jackson laboratory at 10 weeks of age, 
and 24 mice were put into two exposure groups. The first group of 12 mice was exposed 
to CNDs for 1 week and the second group was exposed for 2 weeks. Each major group 
had 3 sub-groups that received IP administration of CNDs. Each group received a daily 
intraperitoneal injection (IP), and all mice were weighed every 3 days. The control group 
of 6 mice received 100 µL sterile saline, and an experimental group of 6 mice received 
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2.5 mg/kg body weight of CND. IP injection used a 27-gauge needle (0.5 in, BD) per 
mouse.  
Animal care involved bedding changes every Tuesday and Friday with full cage 
changes every other week. Animals were given food, and water ad libitum and all 
caretaking were done by the student(s) and Principal investigator. Animals in this project 
were not subjected to any undue stress, pain, or overt discomfort. After the last injection, 
mice were anesthetized using isoflurane and confirmation of sedation was performed by 
the absence of withdrawal reflexes. Cardiac puncture was performed under isoflurane 
anesthesia to collect blood for analysis. After cardiac puncture, the animals did not 
awaken and were euthanized by cervical dislocation. The histopathology of the liver and 
kidneys was carried out by hemoxylin and eosin staining, with samples processed by 
AML Laboratories, Inc. 
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CHAPTER III 
 
RESULTS 
 
 
Characterization of CNDs: UV-Vis and FTIR 
The photoluminescent properties of CNDs can be seen in their excitation 
wavelength of ~370 nm and an emission peak at ~450 nm. At 350 nm, the n-π* transition 
of C=O moieties can be seen in the absorption feature (Fig. 1A). Furthermore, CNDs 
were excited with various wavelengths from 300 – 400 nm and showed a consistent 
emission peak at 450 nm (Fig. 1B). FTIR spectra show the presence of (O-H) and (N-H) 
groups by the presence of broad bands from 3100 – 3400 cm-1. Signals at 690 cm-1, 1375 
cm-1, and 1550 cm-1 are due to the presence of C–C, C=C, and C=O groups, 
respectively. 
CND Uptake by Endothelial Cells 
The entry of CNDs into endothelial cells was measured by an uptake assay that 
involved 6 hour and 12 hour treatments (Fig. 2A). HMEC-1 cells were treated with 0 – 
0.3 mg/mL CNDs and showed a significant (P < 0.05) dose-dependent increase in 
cellular internalization at both time points (Fig. 2B). The intensity of fluorescence at 6 
hours was greater compared to the 12 hour incubation. 
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Monocyte Adhesion Decreases in Response to CND Co-Treatment 
Endothelial cells undergoing inflammatory response synthesize adhesion 
molecules that help bind and extravasate leukocytes to the site of inflammation. This 
assay involved HMEC-1 cells treated with Ox-LDL and measured their adhesion to 
calcein, AM-labeled THP-1 monocytes. HMEC-1 cells treated for 6 hours with Ox-LDL 
showed a significant increase (P < 0.05) in monocyte adhesion at 25 – 50 µg/mL Ox-
LDL, and a significant decrease (P < 0.05) at 75 – 100 µg/mL Ox-LDL (Fig. 3A). Next, 
cells treated with CNDs alone for 6 hours showed a decrease at 0.03 mg/mL CND and no 
significant change at 0.1 – 0.3 mg/mL CNDs (Fig. 3B). Cells were then co-treated for 6 
hours with 50 µg/mL Ox-LDL and 0 – 0.3 mg/mL CNDs and showed a significant 
decrease (P < 0.05) in monocyte adhesion compared to the Ox-LDL group. (Fig. 3C).  
CNDs Decrease Ox-LDL Induced Expression of Cytokine Interleukin-8 
Inflammatory markers such as the cytokine interleukin-8 (IL-8) recruit WBCs to 
the site of inflammation and facilitate atherosclerotic development. Since Ox-LDL is a 
known inducer of inflammation, HMEC-1 cells were treated for different time points 
from 3 – 24 hours with 100 µg/mL Ox-LDL and measured for relative expression IL-8. 
Results from qRT-PCR show IL-8 was induced significantly (P < 0.05) from 24 – 6 
hours of treatment (Fig. 4A). The time point of 6 hours was selected according to HMEC-
1 cells’ response to IL-8 expression. Next, Ox-LDL from 25 – 100 µg/mL was applied to 
HMEC-1 for 6 hours and showed the highest significant (P < 0.05) expression of IL-8 at 
25 µg/mL Ox-LDL (Fig. 4B). HMEC-1 cells treated for 6 hours with CNDs showed a 
significant decrease (P < 0.05) at 0.03 – 0.3 mg/mL CND treatment (Fig. 4C). Then, cells 
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co-treated with CNDs and 25 µg/mL Ox-LDL significantly decrease (P < 0.05) IL-8 
expression compared to the Ox-LDL group (Fig. 4D).  
CND Effect on Cell Viability in HMEC-1 Cells 
The effect of CNDs on HMEC-1 cell viability was assessed using the MTT assay, 
which indicates mitochondrial function. HMEC-1 cells treated for 6 hours with the same 
concentrations showed a significant increase in cell viability at 0.3 mg/mL CND and no 
significant change otherwise (P < 0.05) (Fig. 5). 
Phase II Antioxidative Enzyme Levels in Response to CND Treatment 
The amount of oxidative or reductive stress within a cell is indicated by levels of 
key antioxidants such as glutathione (GSH), glutathione-S-transferase (GST) and 
NAD(P)H dehydrogenase (quinone)-1 (NQO1). HMEC-1 cells were incubated for 12 
hours with 0 – 0.3 mg/mL CNDs and measured for levels of total protein and Phase II 
antioxidant enzyme activity. The concentration of GSH (nmol/mg Protein) did not change 
significantly (P > 0.05) in response to CND treatment (Fig. 6A). The activity of GST 
(Fig. 6B) and NQO1 (Fig. 6C) showed no significant change (P < 0.05) with CND 
concentrations from 0.03 – 0.3 mg/mL compared to the negative control.  
In order to determine NQO1 and GSH levels in response to CNDs, qRT-PCR was 
used to measure relative gene expression in cells. HMEC-1 treated with 0 – 0.3 mg/mL 
CNDs for 6 hours showed no significant change (P < 0.05) in NQO1 levels (Fig. 7A). 
However, the expression of GCL-C at 6 hours post-treatment was decreased significantly 
(P < 0.05) from 0.03 – 0.2 mg/mL CNDs compared to the control (Fig. 7B).  
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The Ability of CNDs to Scavenge ROS as Measured by EPR 
EPR was used to show the generation of ·OH radicals using the Fenton reaction 
(Fe2+/H2O2). The addition of CNDs to the DMPO-hydroxyl radical spin adduct shows a 
significant dose-dependent increase (P < 0.05) in scavenging ability from 0.01 – 0.3 
mg/mL CNDs (Fig. 8A). This is also demonstrated by the EPR spectra showing 
diminishing peaks with increasing doses of CNDs (Fig. 8B). The Xanthine/xanthine 
oxidase (XO) system was used to study the effect of CNDs on Superoxide-scavenging 
activities. The effects of CNDs can be seen in the decrease of DEPMPO-superoxide 
(DEPMPO/O2
-) adduct signal intensity (Fig. 9A). The EPR spectrum signal heights show 
a significant decrease (P < 0.05) with CNDs (0.01 – 0.3 mg/mL CNDs) compared to 
Xan/XO superoxide signal intensity (Fig. 9B).  
Cytoprotective Effects of CNDs in Ox-LDL Induced Toxicity 
The MTT assay was used to analyze the effects of CNDs on cells that were 
treated with cytotoxic concentrations of Ox-LDL. HMEC-1 cells treated for 6 hours with 
Ox-LDL show a dose-dependent decrease (P < 0.05) in viability from 50 – 125 µg/mL 
Ox-LDL (Fig. 10A). Co-treatment with CNDs (0.03 – 0.3 mg/mL) and Ox-LDL (50 
µg/mL) showed a significant increase (P < 0.05) in cell viability from 0.03 – 0.3 mg/mL 
CNDs compared to the Ox-LDL group (Fig. 10B). As demonstrated previously (Fig. 5) 
CNDs alone did not affect cell viability.   
1 and 2 Week CND Exposure of C57BL/6 Mice 
At 10 weeks, male C57BL/6 mice were administered 2.5 mg/kg body weight 
CNDs by intraperitoneal (IP) injection for one (Fig. 11A) and two weeks (Fig. 11B). 
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Their body weight was taken periodically throughout the duration of exposure showed no 
significant change (P >  0.05) compared to the control group, which was given 100 µL 
saline via IP injection. Histological analysis of the kidney and liver focused on 
identifying anomalies between control and experimental groups. The kidney cortex was 
examined mainly on renal tubules and corpuscle. Lobes of the liver were also analyzed 
for central veins and portal triads. All examined structures between control and 
experimental groups were morphologically similar without showing observable 
pathological changes (Fig. 12 & 13).
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CHAPTER IV 
 
DISCUSSION 
 
 
Atherosclerotic development is mediated by the immune response, which 
regulates WBC rolling and adhesion to the site of inflammation. This process is directed 
by chemotactic molecules that guide WBCs and adhesion markers that allow binding to 
ECs leading to their dysfunction. Once monocytes are directed to the underlying 
inflammation, their uptake of Ox-LDL continues the process. Additionally, SMCs and 
ECs can oxidize LDL in the presence of low concentrations of transition metals. This 
accelerates the rate of uptake by monocytes and poses toxicity to ECs and fibroblasts 
[43]. It involves activation by redox signaling, which can cause loss of membrane 
integrity, death, and eventual entry into circulation. Thus, endothelial dysfunction 
influences the initiation and pathological development of atherosclerosis [44].  
The American Heart Association has determined the optimal LDL level as < 100 
mg/dL, and high level as above 190 mg/dL [45]. Ox-LDL is recognized as an autoantigen 
and elicits a strong, chronic inflammatory response via receptor-mediated uptake by 
macrophages [44]. There is an urgent need for effective therapy with minimal side effects 
that targets Ox-LDL generation and pathogenesis as it relates to the development of 
CVD.  As demonstrated in multiple studies, CNDs are a new class of nanomaterials with 
properties that enable their use in biological systems. In this study, we demonstrate that 
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Ox-LDL significantly increases the binding of monocytes to ECs, a major preliminary 
step to atherosclerotic development [43]. The addition of CNDs (0.1 – 0.3 mg/mL) to 
ECs induced with Ox-LDL (50 µg/mL) decreases their adhesion to monocytes, 
demonstrating their anti-inflammatory properties. This implies CNDs can provide 
significant protection against Ox-LDL induced inflammation and resulting pathogenesis. 
The expression of cellular molecules like VCAM-1 and ICAM-1 and secreted 
cytokines such as IL-8 are heavily involved in the regulation of binding, rolling adhesion, 
and extravasation of monocytes into the underlying vascular tissue [46]. The role of IL-8 
in recruiting and activating monocytes during an inflammatory response is demonstrated 
by the prevention of neutrophil extravasation when IL-8 is neutralized [47]. Accordingly, 
IL-8 -/- mice were resistant to developing atherosclerotic plaque, which underscores the 
importance of this cytokine in regulating monocyte adhesion and activation [46].  The 
exposure of HMEC-1s to Ox-LDL (100 µg/mL) increases the relative gene expression of 
IL-8 in a time-dependent manner (Fig. 4A). CND treatment also significantly suppresses 
the Ox-LDL-induced expression of IL-8 (Fig. 4D), and this anti-inflammatory activity of 
CNDs is consistent with their subdual of monocyte adhesion (Fig. 2C).  
This activity of CNDs suggests their role in decreasing inflammatory cytokine 
production and resulting decrease of monocyte adhesion, extravasation, and plaque 
development. The expression of other biomarkers known to play a vital role in EC 
dysfunction and inflammation such as chemokines (MCP-1), cytokines (IL-6) , and 
adhesion molecules (VCAM-1, ICAM-1) remains to be investigated in their response to 
CNDs [48-50].  
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The underlying mechanism of CND suppression of Ox-LDL induced 
inflammation was investigated intracellularly. Given the numerous complex mechanisms 
behind atherosclerosis, excess production of ROS has been shown to be one of the key 
contributing factors to its progression. ROS include superoxide, hydrogen peroxide, 
hydroxyl radical, and peroxynitrite. These species are known to cause oxidation of LDL, 
promoting uptake by macrophages and formation of foam cells [51-53]. Increase in ROS 
can also cause endothelial cell dysfunction and apoptosis, vascular smooth muscle cell 
(SMC) proliferation and migration leading to atherogenesis [51-53].  
The deleterious effects of ROS are countered by the activity of Phase II 
antioxidant enzymes like superoxide dismutase (SOD), glutathione peroxidase (GPx), 
glutathione-S transferase (GST) and NAD(P)H Quinone Dehydrogenase-1 (NQO1). SOD 
isoforms convert H2O2 and superoxide radicals to oxygen. GPx prevents lipid 
peroxidation, decreases EC sensitivity to Ox-LDL and converts lipid peroxides and H2O2 
to lipid alcohols and water. GSH is a tripeptide (L-γ-glutamyl-L-cysteinyl-glycine) and 
acts as a buffer to conserve cellular thiol-disulfide redox capacity. Cellular forms of GSH 
can get oxidized to form glutathione disulfide (GSSG) and further oxidized into 
sulfonates. After GSH is synthesized, it is used to transport xenobiotics through multiple 
organ systems [54]. GST catalyzes the addition of a thiol group from reduced GSH to 
organic compounds. Thus, their hydrophilicity increases and this facilitates the 
detoxification and excretion of xenobiotics [55].  
NQO1 is a flavoprotein that uses NADH or NADPH to perform two-electron 
reduction of quinones and scavenge superoxide radicals. This process is mediated by the 
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Keap1/Nrf2/ARE pathway and reduces the amount of ROS generation via redox cycling 
[56]. It facilitates conjugation in Phase II reactions for stabilization of radicals and 
eventual excretion [57]. In the presence of high cholesterol, these antioxidant enzymes 
are overwhelmed by the production of ROS. The development of drugs has focused on 
lowering cholesterol levels and increasing NOS efficiency, but these methods do not act 
directly on superoxide radicals [45]. 
It was then investigated if the anti-inflammatory action of CNDs could be 
attributed to their modulation of cellular phase II antioxidant enzymes. Thus, HMEC-1s 
treated with CNDs (0.03 – 0.3 mg/mL) were analyzed in regards to the activity of GSH, 
GST, and NQO1. Resulting data showed that CNDs had no significant effect on the 
activity of these antioxidants in HMEC-1s. This suggests the suppression of EC 
dysfunction and inflammation by CNDs is not due to their upregulation of cellular 
antioxidant defense mechanisms. 
The overproduction of ROS causes oxidative stress in cells, which is further 
accelerated by uptake and oxidation of LDL. This process leads to the uptake of Ox-LDL 
particles by macrophages and their development into foam cells that contribute to plaque 
development [51-53]. Thus, it was investigated if the anti-inflammatory effects of CNDs 
are due to their scavenging of superoxide and hydroxyl radicals, which are potent ROS 
species. To this goal, EPR was used with DMPO/DEPMPO-spin trapping to see the 
effect of CNDs in scavenging ·OH and O2
- generated from the Fenton reaction and 
Xanthine Oxidase/Xanthine system, respectively.  
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The DMPO–OH· adduct was represented as EPR spectra that had peaks 
signifying the intensity of ·OH generation using the following reaction: Fe2+ + H2O2 → 
Fe3+ + OH· + OH- (Fig. 8A). The DEPMPO-OOH adduct was represented as spectra with 
peaks indicating the intensity of O2
- radicals generated using the following reaction: Xan 
+ Xo → uric acid + O2
-. The results of EPR indicate that the scavenging ability of CNDs 
(0.003 – 0.3 mg/mL) on ·OH and O2
- radicals increased in a dose-dependent manner. 
This implies CNDs have direct scavenging activity on ROS, which may explain their 
anti-inflammatory effects in vitro. However, there needs to be further investigation on the 
exact mechanism of how the ROS-scavenging activity of CNDs suppresses 
atherosclerotic development.  
 The excess generation of intracellular ROS and uptake of Ox-LDL are shown to 
activate transcription factor NF-κB. The addition of Ox-LDL to ECs causes binding to 
lectin-like ox-LDL receptor-1 (LOX-1) and activates NF-κB [58]. This transcription 
factor is sequestered in the cytoplasm and inhibited by proteins (IkB) until activated by 
phosphorylation. After IkB is degraded, the heterodimers of NF-κB (p50/65) allow NF-
κB translocation to the nucleus and regulation of inflammatory gene transcription [59-
61]. Further investigation is needed to examine if uptake of Ox-LDL by HMEC-1s 
promotes ROS production, resulting in inflammation and if CNDs can suppress NF-κB 
activation by scavenging ROS. 
The cytoprotective effects of CNDs due to their scavenging of ROS was further 
analyzed in HMEC-1s treated with a cytotoxic concentration OxLDL (50 µg/mL). After 
LDL enters ECs, it encounters pro-oxidants that convert it to Ox-LDL, which then 
33 
stimulates more ROS production and subsequent toxicity. When the cellular antioxidant 
defense is overwhelmed, it leads to the activation of signaling cascades involving NF-κB, 
nuclear factor-like 2 (Nrf2)/Kelch-like-ECH-associated protein 1 (Keap 1), and 
phosphoinositide 3-kinase (PI3K)/Akt. These processes lead to the activation of apoptotic 
pathways through activation of cysteine-dependent aspartate-specific proteases (caspases) 
[62]. Previous studies showed that Ox-LDL toxicity in HMEC-1 cells involves calpain 
activation and ubiquitination of caspase 3. This pathway mediated by calpain directs 
proteolysis of cytoskeletal elements, causing apoptosis, the release of cellular ROS and 
downstream development of atherosclerosis [63].  
The effects of CNDs on Ox-LDL-induced cytotoxicity were measured by the 
reduction of MTT by mitochondrial dehydrogenase and NADH. Due to the ROS 
scavenging activity of CNDs, it was investigated if the Ox-LDL induced apoptotic 
pathway in ECs could be decreased or prevented. Incubation of cells with Ox-LDL (0 – 
125 µg/mL) caused a dose-dependent decline in HMEC-1 cell viability due to the 
previously reported pathway. However, CNDs (0.03 – 0.3 mg/mL) were able to increase 
cell viability from 50% in Ox-LDL treated cells to 70 – 80% in cotreated (0.03 – 0.3 
mg/mL CND + 50 µg/mL Ox-LDL) cells, indicating a marked cytoprotective effect. 
These results suggest the mechanism for HMEC-1 cell death could be due to Ox-LDL 
mediated oxidative stress and underscore the ability of CNDs to ameliorate this effect due 
to their ROS scavenging ability.  
As demonstrated by the MTT assay, CND treatment (0 – 1.2 mg/mL) in HMEC-
1s for 6 hours did not show a decrease in cell viability (Fig. 5). In order to observe these 
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effects in vivo, an investigation was performed to study the response of male C57BL/6 
mice (10 wk) to interperitoneal (IP) administration of CNDs for 1 and 2 weeks.  Mice 
were administered 2.5 mg/kg body weight CNDs daily for the duration of each 
experiment and showed no significant change in their body weights compared to the 
control group. The histological analysis focused on two major organs involved in 
detoxification and excretion, the liver and kidney. The effect of CNDs on the renal 
system was evaluated due to the vital filtration functions performed by highly 
vascularized nephrons. The semi-permeable glomerulus and surrounding Bowman’s 
capsule showed no morphological changes compared to control mice. Additionally, 
analysis of portal triads, central veins and sinusoids were performed due to the liver’s 
central role in detoxification. Liver lobules of CND-injected mice and control mice were 
showed no morphological changes or signs of pathology (Fig.12 &13). 
These results in vivo show consistency with previously reported properties of 
CNDs in terms of biocompatibility, hydrophilicity, low toxicity and dose-dependent 
inhibition of tumor proliferation [64]. The optical properties of CNDs demonstrate innate, 
excitation-wavelength independent fluorescent as demonstrated in their consistent 
emission peak at 450 nm. This property was used to demonstrate the concentration-
dependent uptake of CNDs into HMEC-1 cells for 6 and 12 hours (Fig. 2A and B). Thus, 
the fluorescent nature of CNDs enables their potential for use in bio-imaging of various 
tissues, which can provide future insight to biodistribution in vivo [65-68]. 
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CHAPTER V 
 
SUMMARY 
 
 
This study demonstrated that CNDs can significantly reduce Ox-LDL induced 
monocyte adhesion in HMEC-1s, which indicates their anti-inflammatory effect in EC 
dysfunction. The relative gene expression of cytokine IL-8 was reduced by the 
cotreatment of CNDs, which implies their action in mediating monocyte extravasation to 
the site of inflammation. The overproduction of ROS leads to a cascade of signaling 
events that disrupt oxidative balance, induce EC dysfunction, and lead to an 
inflammatory state. Thus, EPR spectroscopy and radical spin-trapping were used to 
demonstrate the superoxide and hydroxyl radical-scavenging ability of CNDs. This 
suggests the anti-inflammatory effects of CNDs seen in vitro are attributed to their direct 
scavenging of ROS. This also allowed CNDs to ameliorate the cytotoxicity posed to 
HMEC-1s by treatment of Ox-LDL and induction of apoptotic pathways. Furthermore, 
CNDs alone did not show signs of cytotoxicity in vitro or vivo as demonstrated by the 
MTT assay and C57BL/6 mice exposure, respectively. The exact cellular and anti-
oxidative mechanism of CNDs remains to be investigated in future studies. The collective 
findings of this study provide evidence for the use of these novel CNDs against Ox-LDL 
mediated inflammation and resulting cardiovascular disease. 
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FIGURES 
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Figure 1. Characterization of CNDs. UV-Vis photoluminescence in a.u. Measured by 
Cary®Eclipse TM Fluorescence Spectrophotometer. (a) Two excitation peaks are seen at 
~220 nm and ~370 nm, and emission peak is ~450 nm. (b) CNDs show emission peak of 
~450 nm with excitation wavelengths from 300 – 400 nm. (c) FTIR spectra indicate (O-
H) and (N-H) groups by the presence of broad bands from 3100 – 3400 cm-1. Signals at 
690 cm-1, 1375 cm-1, and 1550 cm-1 are attributed to C–C, C=C, and C=O groups, 
respectively.  
200 300 400 500 600 700
0
200
400
600
800
1000
Wavelength (nm)
In
te
n
si
ty
 (
a.
u
.)
400 500 600 700
0
200
400
600
800
1000
Wavelength (nm)
In
te
n
si
ty
 (
a.
u
.)
44 
A      B 
  
 
Figure 2. CND Uptake by HMEC-1 Cells. (a) Cells treated with 0 – 0.3 mg/mL CNDs in 
HBSS for 6 hours show a dose-dependent increase in fluorescence intensity. (b) Cells 
treated with 0 – 0.3 mg/mL CNDs in HBSS for 12 hours show a dose-dependent increase 
in fluorescence. All data represent mean ± SEM. (n = 5. *, P < 0.05 vs. control)  
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Figure 3. CNDs Inhibit Ox-LDL-Induced Monocyte Adhesion. (a) HMEC-1 cells were 
treated with Ox-LDL for 6 hrs, and calcein-AM-labeled monocytes were co-incubated for 
1 hr post-treatment. (b) Cells were treated with CNDs for 6 hrs and calcein-AM-labeled 
monocytes were co-incubated for 1 hr post-treatment. (c) HMEC-1 cells were co-treated 
with 50 ug/mL ox-LDL and 0.1 – 0.3 mg/mL CNDs for 6 hrs and calcein-AM-labeled 
monocytes were co-incubated for 1 hr post-treatment. All data represent mean ± SEM. (n 
= 3.*, P < 0.05 vs. control, #, P < 0.05 vs. Ox-LDL)  
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Figure 4. CNDs Decrease HMEC-1 Expression of IL-8 Induced by Ox-LDL. (a) Cells 
treated with 100 ug/mL ox-LDL from 6 – 24 hrs (n = 3) (b) Cells treated with 0 – 100 
ug/mL ox-LDL for 6 hrs (n = 3) (c) Cells treated with 0.03 – 0.3 mg/mL CNDs for 6 
hours (n = 9) (d) HMEC-1 cells were cotreated 25 ug/mL ox-LDL and 0.1 – 0.3 mg/mL 
CNDs for 6 hrs,  (n = 12), All data represent mean ± SEM. (*, P < 0.05 vs. control, #, P 
< 0.05 vs. Ox-LDL)  
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Figure 5. CND Effect on Cell Viability. HMEC-1 treated with CNDs for 6 hours in 
HBSS show a significant increase in viability at 0.3 mg/mL. All data represent mean ± 
SEM. (n = 4,*, P < 0.05 vs. control)  
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Figure 6. Effects of CND Treatment on Phase II Antioxidant Activity. CNDs were 
incubated with HMEC-1 cells for 12 hours in HBSS, and total protein level was 
measured (a) There was no significant change in the amount of glutathione from 0 – 0.3 
mg/mL CNDs. (b) There was no significant change in the activity of GST from 0 – 0.3 
mg/mL CNDs. (c) There was no significant change in the amount of NQO-1 activity from 
0 – 0.3 mg/mL CNDs. All data represent mean ± SEM (n = 4, P < 0.05 vs. control)  
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Figure 7. Effect of CNDs on the Expression of Phase II Antioxidant Genes HMEC-1 
treated with CNDs from 0.03 – 0.3 mg/mL CNDs for 6 hrs in HBSS. (a) There was no 
significant change in NQO1 expression (b) The expression of GCL-C was significantly 
decreased from 0.03 – 0.2 mg/mL CND. All data represent mean ± SEM (n = 12.*, P < 
0.05 vs. control)  
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Figure 8. CND Scavenging Activity on Hydroxyl Radicals. The reaction contained 50 
µM FeSO4 and 50 µM H2O2 (A) EPR spectra show (i) 𝐹𝑒2+/𝐻2𝑂2 (50 µM) only. 
𝐹𝑒2+/𝐻2𝑂2 is in all reactions with the following additions of CNDs (mg/mL) (ii) + 0.003 
(iii) + 0.01 (iv) + 0.03 (v) + 0.1 (vi) + 0.2 (vii) + 0.3 (viii) PBS only (B) Signal intensity 
at 3480 G. All data represent mean ± SEM , n = 3. Turkey’s HSD post hoc test for each 
treatment showed differences (P ≤ 0.05); *, significant differences compared to control  
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Figure 9. CND Scavenging Activities on Superoxide Radicals. The reaction conditions 
and EPR settings were as described in Materials and Methods in the presence of 36 μM 
xanthine and 32 mU/ml xanthine oxidase. (A) EPR spectra of DEPMPO-superoxide spin 
adduct in the absence and presence of CNDs (ii) Xan/XO Superoxide generating system 
(ii) Xan/XO Superoxide generating system + 0.01 mg/mL CND (iii) + 0.03 mg/mL CND 
(iv) PBS only (B) Signal intensity at 3480 G. All data represent mean ± SEM , n = 3. 
Turkey’s HSD post hoc test for each treatment showed differences (P ≤ 0.05); *, 
significant differences compared to control  
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Figure 10. Cytoprotective Effects of CNDs Against Ox-LDL Induced Toxicity. A: 
HMEC-1 were treated with 0 – 100 ug/mL ox-LDL for 6 hrs in HBSS B: HMEC-1 cells 
were cotreated with 50 ug/mL ox-LDL  and 0.03 – 0.3 mg/mL for 6 hrs in HBSS. All data 
represent mean ± SEM (n = 4.*, P < 0.05 vs. control)
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Figure 11. Mice Body Weights of 1 and 2 Week CND Exposure. Mice interperitoneally 
injected with 2.5 mg/mL CNDs/kg bw daily for one week (A) or two weeks (B); Control 
mice injected with 100 µL saline. All data represent mean ± SEM (n = 6. P < 0.05)   
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Figure 12. Week 1 CND Exposure Histology. Mice interperitoneally injected with 2.5 
mg/mL CNDs/kg bw daily for one week; Control mice injected with saline. A: Kidney B: 
Liver.  
55 
 
 
Figure 13. Week 2 CND Exposure Histology. Mice interperitoneally injected with 2.5 
mg/mL CNDs/kg bw daily for two weeks; Control mice injected with saline. A: Kidney B: 
Liver. 
